Phase 3 Non-small Cell Lung Cancer (NSCLC) trials recruiting now

All Non-small Cell Lung Cancer (NSCLC) trials, every phase

Other phases for Non-small Cell Lung Cancer (NSCLC)

Phase 3 Non-small Cell Lung Cancer (NSCLC) trials

• A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
  NCT05920356 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: All (male and female) · 418 locations
• A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
  NCT07566052 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
  NCT07361497 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 259 locations
• A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
  NCT07361510 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 279 locations
• Hippocampal-Sparing Prophylactic Cranial Irradiation in Pathologically Nodal Positive Non-Small-Cell Lung Cancer
  NCT02448992 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
  NCT07154706 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 33 locations
• Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
  NCT07291037 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 205 locations
• Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
  NCT06170788 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 220 locations
• Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC
  NCT07777822 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

What does Phase 3 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.